About ZetaGen
ZetaGen is a company based in Syracuse (United States) founded in 2017. ZetaGen has raised $33.26 million across 7 funding rounds from investors including New York State, National Cancer Institute and Consolidated Investment Group. ZetaGen offers products and services including ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®. ZetaGen operates in a competitive market with competitors including Horizon Therapeutics, Osteal Therapeutics, Angitia, Histogenics and Osiris, among others.
- Headquarter Syracuse, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zetagen Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$33.26 M (USD)
in 7 rounds
-
Latest Funding Round
$12.91 M (USD), Series B
Oct 31, 2025
-
Investors
New York State
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ZetaGen
ZetaGen offers a comprehensive portfolio of products and services, including ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®.
Therapy to suspend cancer and regenerate bone in patients.
Targets primary cancers with potential to minimize side effects.
Treats metastatic breast cancer to reduce tumor burden.
Aids in bone regeneration for cancer-related lesions.
People of ZetaGen
Unlock access to complete
Unlock access to complete
Funding Insights of ZetaGen
ZetaGen has successfully raised a total of $33.26M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $12.91 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ZetaGen
ZetaGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include New York State, National Cancer Institute and Consolidated Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Provides the information about government agencies in New York
|
Locked | Locked | Locked | |
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked |
Investor details for ZetaGen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ZetaGen
Investment portfolio details for ZetaGen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ZetaGen
Detailed financials for ZetaGen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zetagen Comparisons
Peer comparison for ZetaGen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ZetaGen
ZetaGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, Osteal Therapeutics, Angitia, Histogenics and Osiris, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections
|
|
| Locked | Locked | Locked |
Drugs for muscle, bone, and joint diseases are developed.
|
|
| Locked | Locked | Locked |
Restorative cell therapies for orthopedic diseases are developed.
|
|
| Locked | Locked | Locked |
Stem cell-based regenerative medicines are developed and marketed.
|
Detailed competitors of ZetaGen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zetagen
Complete news archive for ZetaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZetaGen
ZetaGen was founded in 2017 and raised its 1st funding round 1 year after it was founded.
ZetaGen is headquartered in Syracuse, United States. It is registered at Syracuse, New York, United States.
ZetaGen is a funded company, having raised a total of $33.26M across 7 funding rounds to date.
ZetaGen was founded in 2017 and is based in Syracuse, United States. Small molecule-based therapeutics are developed by the company for bone regeneration, targeting injuries, procedures, and diseases. A molecular pathway is activated by these drugs, while osteoclast activity is down-regulated to reduce bone destruction. Operations focus on the biotechnology sector, with emphasis on orthopedic applications.
ZetaGen's top competitors include Horizon Therapeutics, Angitia and Osiris.
ZetaGen offers ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®.
ZetaGen has 3 investors. Key investors include New York State, National Cancer Institute, and Consolidated Investment Group.